Related Experiment Video

Updated: Aug 14, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents

Jay Rhee1, Karen Oishi, Jody Garey

  • 1University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Clinical Colorectal Cancer
|December 13, 2005
PubMed

Insights

Epidermal growth factor receptor (EGFR) inhibitors cause skin rash, a common side effect. This study proposes a treatment strategy to manage rash, allowing patients to continue cancer therapy without interruption.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) inhibitors are crucial in cancer therapy.
  • EGFR inhibitors, including monoclonal antibodies and small-molecule tyrosine kinase inhibitors (TKIs), target the ErbB receptor family.
  • These therapies cause dermatologic side effects, distinct from chemotherapy's bone marrow suppression.

Purpose of the Study:

  • To clarify the relationship between rash and EGFR inhibitor toxicity and response.
  • To address the controversy surrounding the optimal management of rash in patients undergoing anti-EGFR therapy.
  • To propose an aggressive treatment strategy for dermatologic side effects to maintain therapeutic continuity.

Main Methods:

  • Review of current literature on EGFR inhibitor-induced dermatologic toxicities.
  • Analysis of clinical trial data regarding rash management.
  • Development of a proposed treatment algorithm for managing EGFR inhibitor-associated rash.

Main Results:

  • Dermatologic side effects, particularly rash, are common with EGFR inhibitors.
  • Current management strategies for rash are often imprecise and lack robust clinical trial support.
  • An aggressive treatment approach may allow patients to continue EGFR inhibitor therapy without dose modification.

Conclusions:

  • Effective management of rash is essential for sustained anti-EGFR therapy.
  • Further clinical trials are needed to establish optimal treatment algorithms for EGFR inhibitor-induced rash.
  • The proposed strategy aims to mitigate toxicity and improve patient adherence to cancer treatment.

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...